Anaphylactic reaction to synthetic luteinizing hormone-releasing hormone

MacLeod, Tara L.; Eisen, A. H.; Sussman, Gordon

doi:10.1016/s0015-0282(16)59428-x

Cited by 21 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first involves a 28-year-old woman with polycystic ovarian syndrome who experienced anaphylaxis and required intensive care monitoring after her fourth course of treatment (after three uneventful courses). 10 Skin-prick testing was consistent with an IgE-mediated reaction. The second report describes an IgEmediated urticarial reaction that occurred after 6 months of therapy in a 26-year-old with hypogonadotropic hypogonadism.…”

Section: Discussionmentioning

confidence: 90%

“…These reports support the diagnosis of IgE-mediated anaphylaxis in response to goserelin acetate in our patient. [6][7][8][9][10][11] We know of only one other published case report that describes hypersensitivity to goserelin acetate. 7 It involved a 36-year-old woman who received monthly subcutaneous injections of goserelin acetate 3.6 mg for treatment of endometriosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Lam

Tjon²,

Hamilton

et al. 2006

Pharmacotherapy

View full text Add to dashboard Cite

An 8-year-old girl with idiopathic central precocious puberty experienced multiple episodes of anaphylaxis after receiving a goserelin acetate implant. She was hospitalized and treated with epinephrine, antihistamine, and corticosteroids. The goserelin implant was surgically excised; however, anaphylactic symptoms continued for 4 days after excision. Less severe systemic symptoms recurred 6 weeks after removal; these were possibly due to leakage of the depot drug into subcutaneous tissues. It was noted that 3 years earlier, the patient had developed a similar, milder systemic allergic reaction to leuprolide acetate that required treatment with oral prednisone and antihistamines. Intradermal testing yielded positive results for leuprolide. Gonadotropin-releasing hormone (GnRH) analogs, including leuprolide acetate and goserelin acetate, are commonly prescribed for patients with prostatic carcinoma, endometriosis, and precocious puberty. A literature review identified a single case report of a systemic hypersensitivity reaction involving goserelin acetate and several reports of systemic hypersensitivity reactions associated with leuprolide acetate. We found no reports of systemic reactions to GnRH analogs in pediatric patients. Clinicians should be aware of the potential association of GnRH analogs with systemic reactions. They should also recognize that recurrent anaphylaxis may occur due to the long half-life of these therapeutic agents in tissue.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Lam

Tjon²,

Hamilton

et al. 2006

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…2000; Thompson 2001). Other rarely reported side effects of LHRH agonists include angina and myocardial infarction (Pierce 1995), anaphylactic reactions (MacLeod et al. 1987) and temporary renal impairment (Reilly et al.…”

Section: Androgen Depleting Drugs (Adds)mentioning

confidence: 99%

“…This 'flare effect' which might result in increased sex drive in the first 2-3 weeks of initiation of treatment can be effectively prevented by administration of flutamide (a pure androgen receptor antagonist) or CPA starting a week before, and continuing for 2-4 weeks after the initiation of LHRH agonist therapy (Reilly et al 2000;Thompson 2001). Other rarely reported side effects of LHRH agonists include angina and myocardial infarction (Pierce 1995), anaphylactic reactions (MacLeod et al 1987) and temporary renal impairment (Reilly et al 2000). Very rarely, pituitary apoplexy, an acute condition characterised by sudden headache, neck stiffness, vomiting and visual impairment caused by rapid enlargement of undetected pituitary adenomas, probably related to the acute stimulating effect occurring with the initiation of the therapy have been reported with LHRH use (Morsi et al 1996).…”

Section: Adverse Effects and Contraindications Of Addsmentioning

confidence: 99%

Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities

Sajith

Morgan

Clarke

2008

J intellect Disabil Res

View full text Add to dashboard Cite

The quality of evidence base for the use of pharmacological agents in the treatment of ISBs is inadequate to justify their use in routine clinical practice. If used, they should only be a part of a comprehensive treatment programme and closely monitored. In addition, there are several clinical, ethical and legal issues to be addressed before considering pharmacological treatment of ISBs in people with ID.

show abstract

“…In 1985, Meakin [36] reported that out of 163 patients treated with GnRH, 5 (3 men and 2 women) had specific IgG binding to labelled GnRH, suggesting that a 3% prevalence rate of GnRH antibody forma tion could occur after GnRH therapy. More recently, a case of immune anaphylactic reaction to GnRH was reported [37].…”

Section: Administration and Dosagementioning

confidence: 99%

Induction of Ovulation – Past, Present and Future

Jewelewicz¹,

Gindoff²

1988

Gynecol Obstet Invest

View full text Add to dashboard Cite

Attempts to induce ovulation have been made since the early 1920s, but the major breakthrough came in the early 1960s with the introduction of clomiphene citrate and the gonadotropins. Additional progress was made in the early 1970s with the introduction of bromocriptine and in the early 1980s with the introduction of pulsatile GnRH. At the present, ‘pure’ FSH and GnRH agonists are being evaluated as adjuncts to HMG for induction of ovulation. As more insight is gained in the neuroendocrine control of the ovulating cycle, we may soon be able to induce ovulation by direct manipulation of the central nervous system.

show abstract

Anaphylactic reaction to synthetic luteinizing hormone-releasing hormone

Cited by 21 publications

References 4 publications

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities

Induction of Ovulation – Past, Present and Future

Contact Info

Product

Resources

About

Anaphylactic reaction to synthetic luteinizing hormone-releasing hormone

Cited by 21 publications

References 4 publications

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature

Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities

Induction of Ovulation &ndash; Past, Present and Future

Contact Info

Product

Resources

About

Induction of Ovulation – Past, Present and Future